What is the price-to-earnings ratio of Oragenics?
The price-earnings ratio of Oragenics is currently -3.2.
Oragenics P/E 2024
Oragenics P/E
-3.2
Ticker
OGEN
ISIN
US6840233026
WKN
A2JBK2
As of Dec 30, 2024, Oragenics's P/E ratio was -3.2, a 932.26% change from the -0.31 P/E ratio recorded in the previous year.
The Oragenics P/E history
Oragenics Aktienanalyse
What does Oragenics do?
Oragenics Inc is a biopharmaceutical company that focuses on the development of innovative technologies and products for the prevention and treatment of oral and systemic infectious diseases. The company was founded in 1996 as a private company and has since had an impressive track record in the development of diagnostic tools and therapeutics for various diseases in different fields. The company's business model is based on the identification and development of therapeutics that leverage innovative technologies such as bacterial toxins and probiotics. Their products aim to address both the causes of disease formation and the symptoms, contributing to improved patient well-being. Oragenics maintains partnerships and collaborations with other companies and research institutions to enhance its research and development efforts. The company is divided into multiple divisions, including the development of probiotic bacterial groups with specific immunotherapeutic functions, the development of biopharmaceutical products for the treatment of infectious diseases, and the development of diagnostics and screening tools for identifying oral infections. Oragenics has developed a range of products and technologies that can contribute to the improvement of oral and overall health, including a Streptococcus mutans detection system for dentists to identify and combat bacteria in the patient's mouth. One notable product is the TerraCoV2 COVID-19 vaccine, developed in collaboration with the National University of Singapore. Overall, Oragenics Inc has a remarkable track record in the development of innovative technologies and products, emphasizing product quality, rational manufacturing, and a wide range of medical devices. The company works closely with partners and collaborators to intensify its research and development efforts and provide innovative solutions and products. Oragenics ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/E Details
Deciphering Oragenics's P/E Ratio
The Price to Earnings (P/E) Ratio of Oragenics is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.
Year-to-Year Comparison
Assessing Oragenics's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.
Impact on Investments
The P/E ratio of Oragenics is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.
Interpreting P/E Ratio Fluctuations
Fluctuations in Oragenics’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.
Frequently Asked Questions about Oragenics stock
How has the price-earnings ratio of Oragenics changed compared to last year?
The price-to-earnings ratio of Oragenics has increased by 932.26% increased compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Oragenics high compared to other companies?
Yes, the price-to-earnings ratio of Oragenics is high compared to other companies.
How does an increase in the price-earnings ratio of Oragenics affect the company?
An increase in the price-earnings ratio of Oragenics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Oragenics affect the company?
A decrease in the price-earnings ratio of Oragenics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Oragenics?
Some factors that influence the price-earnings ratio of Oragenics are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Oragenics pay?
Over the past 12 months, Oragenics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Oragenics is expected to pay a dividend of 0 USD.
What is the dividend yield of Oragenics?
The current dividend yield of Oragenics is .
When does Oragenics pay dividends?
Oragenics pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Oragenics?
Oragenics paid dividends every year for the past 0 years.
What is the dividend of Oragenics?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Oragenics located?
Oragenics is assigned to the 'Health' sector.
Wann musste ich die Aktien von Oragenics kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Oragenics from 12/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/30/2024.
When did Oragenics pay the last dividend?
The last dividend was paid out on 12/30/2024.
What was the dividend of Oragenics in the year 2023?
In the year 2023, Oragenics distributed 0 USD as dividends.
In which currency does Oragenics pay out the dividend?
The dividends of Oragenics are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Oragenics
Our stock analysis for Oragenics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Oragenics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
